NASDAQ:AAPG Ascentage Pharma Group International (AAPG) Stock Price, News & Analysis $27.30 +2.08 (+8.25%) As of 11:58 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Ascentage Pharma Group International Stock (NASDAQ:AAPG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AAPG alerts:Sign Up Key Stats Today's Range$26.82▼$27.4950-Day Range$17.70▼$26.4852-Week Range$16.50▼$27.49Volume10,029 shsAverage Volume58,947 shsMarket Capitalization$2.38 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company OverviewAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Read More… Receive AAPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascentage Pharma Group International and its competitors with MarketBeat's FREE daily newsletter. Email Address AAPG Stock News HeadlinesLive from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral ReportJune 2 at 7:30 PM | globenewswire.comLive from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid TumorsJune 2 at 7:30 PM | globenewswire.comBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.June 3, 2025 | Stansberry Research (Ad)Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025May 22, 2025 | globenewswire.comIs Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now?May 12, 2025 | msn.comAscentage Pharma Group International ADRApril 30, 2025 | morningstar.comAscentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with LisaftoclaxApril 28, 2025 | globenewswire.comHigh Growth Tech Stocks in Asia to Watch This April 2025April 25, 2025 | finance.yahoo.comSee More Headlines AAPG Stock Analysis - Frequently Asked Questions How have AAPG shares performed this year? Ascentage Pharma Group International's stock was trading at $18.67 at the beginning of the year. Since then, AAPG shares have increased by 44.1% and is now trading at $26.91. View the best growth stocks for 2025 here. When did Ascentage Pharma Group International IPO? Ascentage Pharma Group International (AAPG) raised $126 million in an IPO on Friday, January 24th 2025. The company issued 7,325,000 shares at a price of $17.25 per share. When does the company's lock-up period expire? Ascentage Pharma Group International's lock-up period expires on Wednesday, July 23rd. Ascentage Pharma Group International had issued 7,325,000 shares in its public offering on January 24th. The total size of the offering was $126,356,250 based on an initial share price of $17.25. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted. Who are Ascentage Pharma Group International's major shareholders? Top institutional shareholders of Ascentage Pharma Group International include Monashee Investment Management LLC (0.18%). How do I buy shares of Ascentage Pharma Group International? Shares of AAPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AAPG Previous SymbolNASDAQ:AAPG CIK2023311 WebN/A Phone86 512 8555 7777FaxN/AEmployees600Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$980.65 million Price / Sales2.24 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares87,112,000Free FloatN/AMarket Cap$2.20 billion OptionableN/A BetaN/A These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:AAPG) was last updated on 6/3/2025 by MarketBeat.com Staff From Our PartnersDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind ...Altimetry | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Real Reason Silver Prices Are SoaringElon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.